Benitec Biopharma Inc. (BNTC)
- Previous Close
13.14 - Open
13.36 - Bid 9.42 x 200
- Ask 15.96 x 200
- Day's Range
12.30 - 14.00 - 52 Week Range
5.74 - 16.90 - Volume
41,005 - Avg. Volume
45,913 - Market Cap (intraday)
336.7M - Beta (5Y Monthly) 0.34
- PE Ratio (TTM)
-- - EPS (TTM)
-0.62 - Earnings Date May 14, 2025 - May 16, 2025
- Forward Dividend & Yield --
- Ex-Dividend Date --
- 1y Target Est
25.71
Benitec Biopharma Inc., a clinical-stage biotechnology company, focuses on the development of novel genetic medicines. The company develops DNA-directed RNA interference-based therapeutics for chronic and life-threatening human conditions. It is developing BB-301, an adeno-associated virus based gene therapy agent for treating oculopharyngeal muscular dystrophy. Benitec Biopharma Inc. was incorporated in 1995 and is headquartered in Hayward, California.
benitec.comRecent News: BNTC
View More
Performance Overview: BNTC
Trailing total returns as of 5/13/2025, which may include dividends or other distributions. Benchmark is S&P 500 (^GSPC) .
YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: BNTC
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: BNTC
View MoreValuation Measures
Market Cap
336.70M
Enterprise Value
258.55M
Trailing P/E
--
Forward P/E
--
PEG Ratio (5yr expected)
--
Price/Sales (ttm)
--
Price/Book (mrq)
4.43
Enterprise Value/Revenue
--
Enterprise Value/EBITDA
--
Financial Highlights
Profitability and Income Statement
Profit Margin
0.00%
Return on Assets (ttm)
-29.99%
Return on Equity (ttm)
-46.85%
Revenue (ttm)
--
Net Income Avi to Common (ttm)
-21.41M
Diluted EPS (ttm)
-0.62
Balance Sheet and Cash Flow
Total Cash (mrq)
78.28M
Total Debt/Equity (mrq)
0.18%
Levered Free Cash Flow (ttm)
-15.39M